The litigation centers on a significant disconnect between the firm’s reported business fundamentals and its market performance. While Park Ha Biological Technology commanded a market capitalization exceeding $1 billion at its peak, the company reported only 39 franchise locations as of April 30, 2025. Furthermore, franchise fee revenue for the six months ending April 30, 2024, totaled just $551,970, a decrease from the $1,146,368 recorded during the same period the previous year.
On July 8, 2025, shares plummeted $38.02 to close at $2.99 on volume exceeding 8.9 million shares. The complaint alleges that the company's valuation lacked any supporting corporate developments or financial milestones, raising questions regarding the accuracy of information provided to investors during the class period. Shareholders seeking to serve as lead plaintiff in the Southern District of New York action must file their requests by September 28, 2026.
Comments (0)
No comments yet. Be the first!